Related references
Note: Only part of the references are listed.High efficacy and safety of CD38 and BCMA bispecific CAR-T in relapsed or refractory multiple myeloma
Yuanyan Tang et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2022)
Trispecific T-cell engagers for dual tumor-targeting of colorectal cancer
Antonio Tapia-Galisteo et al.
ONCOIMMUNOLOGY (2022)
The antigen-binding moiety in the driver's seat of CARs
Heleen Hanssens et al.
MEDICINAL RESEARCH REVIEWS (2022)
Half-Life Extended Nanobody-Based CD38-Specific Bispecific Killercell Engagers Induce Killing of Multiple Myeloma Cells
Julia Hambach et al.
FRONTIERS IN IMMUNOLOGY (2022)
Four-year follow-up of LCAR-B38M in relapsed or refractory multiple myeloma: a phase 1, single-arm, open-label, multicenter study in China (LEGEND-2)
Wan-Hong Zhao et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2022)
CD38 as a multifaceted immunotherapeutic target in CLL
Aneel Paulus et al.
LEUKEMIA & LYMPHOMA (2022)
BiTEs, DARTS, BiKEs and TriKEs-Are Antibody Based Therapies Changing the Future Treatment of AML?
Cecily Allen et al.
LIFE-BASEL (2021)
Preclinical Characterization of HPN536, a Trispecific, T-Cell-Activating Protein Construct for the Treatment of Mesothelin-Expressing Solid Tumors
Mary Ellen Molloy et al.
CLINICAL CANCER RESEARCH (2021)
AMG 757, a Half-Life Extended, DLL3-Targeted Bispecific T-Cell Engager, Shows High Potency and Sensitivity in Preclinical Models of Small-Cell Lung Cancer
Michael J. Giffin et al.
CLINICAL CANCER RESEARCH (2021)
Preclinical Evaluation of Invariant Natural Killer T Cells Modified with CD38 or BCMA Chimeric Antigen Receptors for Multiple Myeloma
Renee Poels et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Daratumumab and Nanobody-Based Heavy Chain Antibodies Inhibit the ADPR Cyclase but not the NAD+ Hydrolase Activity of CD38-Expressing Multiple Myeloma Cells
Natalie Baum et al.
CANCERS (2021)
A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma
Heng Mei et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)
A non-internalised CD38-binding radiolabelled single-domain antibody fragment to monitor and treat multiple myeloma
Elodie Duray et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Annotating BCMA Expression in Multiple Myelomas
Weijun Wei et al.
MOLECULAR PHARMACEUTICS (2021)
CD38 and Regulation of the Immune Response Cells in Cancer
Sanyog Dwivedi et al.
JOURNAL OF ONCOLOGY (2021)
The Application of Nanobody in CAR-T Therapy
Chaolemeng Bao et al.
BIOMOLECULES (2021)
Programmable half-life and anti-tumour effects of bispecific T-cell engager-albumin fusions with tuned FcRn affinity
Ole A. Mandrup et al.
COMMUNICATIONS BIOLOGY (2021)
Keeping Myeloma in Check: The Past, Present and Future of Immunotherapy in Multiple Myeloma
James Ackley et al.
CANCERS (2021)
Incorporation of a Novel CD16-Specific Single-Domain Antibody into Multispecific Natural Killer Cell Engagers With Potent ADCC
Henk van Faassen et al.
MOLECULAR PHARMACEUTICS (2021)
A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab
Joseph Mikhael et al.
BLOOD CANCER JOURNAL (2021)
Targeting BCMA in Multiple Myeloma
Carlyn Rose Tan et al.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2021)
Mouse CD38-Specific Heavy Chain Antibodies Inhibit CD38 GDPR-Cyclase Activity and Mediate Cytotoxicity Against Tumor Cells
Natalie Baum et al.
FRONTIERS IN IMMUNOLOGY (2021)
A HER2 Tri-Specific NK Cell Engager Mediates Efficient Targeting of Human Ovarian Cancer
Daniel A. Vallera et al.
CANCERS (2021)
Balancing the CD38 Expression on Effector and Target Cells in Daratumumab-Mediated NK Cell ADCC against Multiple Myeloma
Margaux Lejeune et al.
CANCERS (2021)
3-weekly daratumumab-lenalidomide/pomalidomide-dexamethasone is highly effective in relapsed and refractory multiple myeloma
Chor Sang Chim et al.
HEMATOLOGY (2021)
Pre-arrayed Pan-AAV Peptide Display Libraries for Rapid Single-Round Screening
Kathleen Boerner et al.
MOLECULAR THERAPY (2020)
Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma
Ilaria Saltarella et al.
CELLS (2020)
Targeting CD38-Expressing Multiple Myeloma and Burkitt Lymphoma Cells In Vitro with Nanobody-Based Chimeric Antigen Receptors (Nb-CARs)
Julia Hambach et al.
CELLS (2020)
The BiTE (Bispecific T-Cell engager) platform: development and future potential of a targeted immuno-oncology therapy across Tumor Types
Hermann Einsele et al.
CANCER (2020)
Systematically optimized BCMA/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma
Eugenia Zah et al.
NATURE COMMUNICATIONS (2020)
Engineering CAR-T Cells for Next-Generation Cancer Therapy
Mihe Hong et al.
CANCER CELL (2020)
Use of Cell and Genome Modification Technologies to Generate Improved Off-the-Shelf CAR T and CAR NK Cells
Michael A. Morgan et al.
FRONTIERS IN IMMUNOLOGY (2020)
CD38 in cancer-associated fibroblasts promotes pro-tumoral activity
Bar Ben Baruch et al.
LABORATORY INVESTIGATION (2020)
Gene therapy for Alzheimer's disease targeting CD33 reduces amyloid beta accumulation and neuroinflammation
Ana Griciuc et al.
HUMAN MOLECULAR GENETICS (2020)
BCMA-targeted immunotherapy for multiple myeloma
Bo Yu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
CAR-NK cells: A promising cellular immunotherapy for cancer
Guozhu Xie et al.
EBIOMEDICINE (2020)
Evaluation of P2X7 Receptor Function in Tumor Contexts Using rAAV Vector and Nanobodies (AAVnano)
Melanie Demeules et al.
FRONTIERS IN ONCOLOGY (2020)
Trispecific killer engager 161519 enhances natural killer cell function and provides anti-tumor activity against CD19-positive cancers
Ying Cheng et al.
CANCER BIOLOGY & MEDICINE (2020)
Nanobody-based CD38-specific heavy chain antibodies induce killing of multiple myeloma and other hematological malignancies
Levin Schriewer et al.
THERANOSTICS (2020)
CD38 as a therapeutic target for adult acute myeloid leukemia and T-cell acute lymphoblastic leukemia
Jyoti Naik et al.
HAEMATOLOGICA (2019)
Nanobody Targeting of Epidermal Growth Factor Receptor (EGFR) Ectodomain Variants Overcomes Resistance to Therapeutic EGFR Antibodies
Joseph Tintelnot et al.
MOLECULAR CANCER THERAPEUTICS (2019)
leExploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma
Jie Xu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Novel targets for the treatment of relapsing multiple myeloma
Nicola Giuliani et al.
EXPERT REVIEW OF HEMATOLOGY (2019)
Multiple myeloma: Every year a new standard?
S. Vincent Rajkumar
HEMATOLOGICAL ONCOLOGY (2019)
Natural Killer Cells as Allogeneic Effectors in Adoptive Cancer Immunotherapy
Kyle B. Lupo et al.
CANCERS (2019)
Killers 2.0: NK cell therapies at the forefront of cancer control
Jonathan J. Hodgins et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Nanobody-Enhanced Targeting of AAV Gene Therapy Vectors
Anna Marei Eichhoff et al.
MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT (2019)
Toward personalized treatment in multiple myeloma based on molecular characteristics
Charlotte Pawlyn et al.
BLOOD (2019)
CD38 Expression by Myeloma Cells and Its Role in the Context of Bone Marrow Microenvironment: Modulation by Therapeutic Agents
Federica Costa et al.
CELLS (2019)
David vs. Goliath: The Structure, Function, and Clinical Prospects of Antibody Fragments
Adam Bates et al.
ANTIBODIES (2019)
Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond
C. S. Chim et al.
LEUKEMIA (2018)
High-Throughput Dissection of AAV-Host Interactions: The Fast and the Curious
Anne-Kathrin Herrmann et al.
JOURNAL OF MOLECULAR BIOLOGY (2018)
The less-is-more in therapeutic antibodies: Afucosylated anti-cancer antibodies with enhanced antibody-dependent cellular cytotoxicity
Natasha A. Pereira et al.
MABS (2018)
CD38-Mediated Immunosuppression as a Mechanism of Tumor Cell Escape from PD-1/PD-L1 Blockade
Limo Chen et al.
CANCER DISCOVERY (2018)
Emerging Issues in AAV-Mediated In Vivo Gene Therapy
Pasqualina Colella et al.
MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT (2018)
Anti-Multiple Myeloma Activity of Nanobody-Based Anti-CD38 Chimeric Antigen Receptor T Cells
Na An et al.
MOLECULAR PHARMACEUTICS (2018)
A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma
Wan-Hong Zhao et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
Perspectives for the Development of CD38-Specific Heavy Chain Antibodies as Therapeutics for Multiple Myeloma
Peter Bannas et al.
FRONTIERS IN IMMUNOLOGY (2018)
CD38-Specific Biparatopic Heavy Chain Antibodies Display Potent Complement-Dependent Cytotoxicity Against Multiple Myeloma Cells
Kerstin Schuetze et al.
FRONTIERS IN IMMUNOLOGY (2018)
CD38 antibodies in multiple myeloma: back to the future
Niels W. C. J. van de Donk et al.
BLOOD (2018)
161533 TriKE stimulates NK-cell function to overcome myeloid-derived suppressor cells in MDS
Dhifaf Sarha et al.
BLOOD ADVANCES (2018)
Long-term CD38 saturation by daratumumab interferes with diagnostic myeloma cell detection
Anna Oberle et al.
HAEMATOLOGICA (2017)
T cells bearing anti-CD19 and/or anti-CD38 chimeric antigen receptors effectively abrogate primary double-hit lymphoma cells
Keichiro Mihara et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
Intracranial AAV-IFN-β gene therapy eliminates invasive xenograft glioblastoma and improves survival in orthotopic syngeneic murine model
Dwijit GuhaSarkar et al.
MOLECULAR ONCOLOGY (2017)
A Rational Strategy for Reducing On-Target Off-Tumor Effects of CD38-Chimeric Antigen Receptors by Affinity Optimization
Esther Drent et al.
MOLECULAR THERAPY (2017)
A synthetic AAV vector enables safe and efficient gene transfer to the mammalian inner ear
Lukas D. Landegger et al.
NATURE BIOTECHNOLOGY (2017)
Long-term CD38 saturation by daratumumab interferes with diagnostic myeloma cell detection
Anna Oberle et al.
HAEMATOLOGICA (2017)
Nanobodies and Nanobody-Based Human Heavy Chain Antibodies As Antitumor Therapeutics
Peter Bannas et al.
FRONTIERS IN IMMUNOLOGY (2017)
Nanobodies effectively modulate the enzymatic activity of CD38 and allow specific imaging of CD38+tumors in mouse models in vivo
William Fumey et al.
SCIENTIFIC REPORTS (2017)
Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab
Jakub Krejcik et al.
CLINICAL CANCER RESEARCH (2017)
NK-92: an 'off-the-shelf therapeutic' for adoptive natural killer cell-based cancer immunotherapy
Garnet Suck et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2016)
Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma
Jakub Krejcik et al.
BLOOD (2016)
A novel bispecific antibody, BiSS, with potent anti-cancer activities
Bin Dong et al.
CANCER BIOLOGY & THERAPY (2016)
IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing Persistence, In Vivo Expansion, and Enhanced Function
Daniel A. Vallera et al.
CLINICAL CANCER RESEARCH (2016)
Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies
Marco Ruella et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
A dual AAV system enables the Cas9-mediated correction of a metabolic liver disease in newborn mice
Yang Yang et al.
NATURE BIOTECHNOLOGY (2016)
Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura
Flora Peyvandi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Multiple myeloma epidemiology and survival: A unique malignancy
Dickran Kazandjian
SEMINARS IN ONCOLOGY (2016)
TriKEs and BiKEs join CARs on the cancer immunotherapy highway
Szun Szun Tay et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2016)
Natural Killer Cells for immunotherapy-Advantages of the NK-92 Cell Line over Blood NK Cells
Hans Klingemann et al.
FRONTIERS IN IMMUNOLOGY (2016)
Molecular imaging of tumors with nanobodies and antibodies: Timing and dosage are crucial factors for improved in vivo detection
Peter Bannas et al.
CONTRAST MEDIA & MOLECULAR IMAGING (2015)
Addressing challenges of heterogeneous tumor treatment through bispecific protein-mediated pretargeted drug delivery
Qi Yang et al.
JOURNAL OF CONTROLLED RELEASE (2015)
Fusion of hIgG1-Fc to In-111-anti-amyloid single domain antibody fragment VHH-pa2H prolongs blood residential time in APP/PS1 mice but does not increase brain uptake
Maarten Rotman et al.
NUCLEAR MEDICINE AND BIOLOGY (2015)
In vivo near-infrared fluorescence targeting of T cells: comparison of nanobodies and conventional monoclonal antibodies
Peter Bannas et al.
CONTRAST MEDIA & MOLECULAR IMAGING (2014)
Vectored immunoprophylaxis protects humanized mice from mucosal HIV transmission
Alejandro B. Balazs et al.
NATURE MEDICINE (2014)
Imaging of multiple myeloma: Current concepts
Thorsten Derlin et al.
WORLD JOURNAL OF ORTHOPEDICS (2014)
Comparative diagnostic performance of 18F-FDG PET/CT versus whole-body MRI for determination of remission status in multiple myeloma after stem cell transplantation
Thorsten Derlin et al.
EUROPEAN RADIOLOGY (2013)
Single-Domain Antibody-Based and Linker-Free Bispecific Antibodies Targeting FcγRIII Induce Potent Antitumor Activity without Recruiting Regulatory T Cells
Caroline Rozan et al.
MOLECULAR CANCER THERAPEUTICS (2013)
Displaying High-affinity Ligands on Adeno-associated Viral Vectors Enables Tumor Cell-specific and Safe Gene Transfer
Robert C. Muench et al.
MOLECULAR THERAPY (2013)
Diagnostic performance of whole-body MRI for the detection of persistent or relapsing disease in multiple myeloma after stem cell transplantation
Peter Bannas et al.
EUROPEAN RADIOLOGY (2012)
Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors
Michel de Weers et al.
JOURNAL OF IMMUNOLOGY (2011)
Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges
Federico Mingozzi et al.
NATURE REVIEWS GENETICS (2011)
A Case Of Convergence: Why Did a Simple Alternative to Canonical Antibodies Arise in Sharks and Camels?
Martin F. Flajnik et al.
PLOS BIOLOGY (2011)
General Strategy to Humanize a Camelid Single-domain Antibody and Identification of a Universal Humanized Nanobody Scaffold
Cecile Vincke et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
Isolation and characterization of anti-Fc gamma RIII (CD16) llama single-domain antibodies that activate natural killer cells
Ghislaine Behar et al.
PROTEIN ENGINEERING DESIGN & SELECTION (2008)
High concentrations of therapeutic IgG1 antibodies are needed to compensate for inhibition of antibody-dependent cellular cytotoxicity by excess endogenous immunoglobulin G
S Preithner et al.
MOLECULAR IMMUNOLOGY (2006)
Use of genetic immunization to raise antibodies recognizing toxin-related cell surface ADP-ribosyltransferases in native conformation
F Koch-Nolte et al.
CELLULAR IMMUNOLOGY (2005)
Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma
WK Weng et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Conjugate-based targeting of recombinant adeno-associated virus type 2 vectors by using avidin-linked ligands
S Ponnazhagan et al.
JOURNAL OF VIROLOGY (2002)
Adeno-associated virus capsids displaying immunoglobulin-binding domains permit antibody-mediated vector retargeting to specific cell surface receptors
MU Ried et al.
JOURNAL OF VIROLOGY (2002)
Camel single-domain antibodies as modular building units in bispecific and bivalent antibody constructs
KE Conrath et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Stability engineering of antibody single-chain Fv fragments
A Wörn et al.
JOURNAL OF MOLECULAR BIOLOGY (2001)
Share Paper
